<DOC>
	<DOCNO>NCT01890772</DOCNO>
	<brief_summary>This study people diagnose chronic hepatitis C , specifically certain type virus , genotype 1 , yet receive treatment hepatitis C. This pilot study design test whether addition vitamin D , three drug ( Incivek ( telaprevir ) , Pegasys ( peginterferon alfa-2a ) , ribavirin ) approve Food Drug Administration ( FDA ) treatment hepatitis C , help eliminate HCV body . Currently , doctor unsure addition vitamin D prescribe hepatitis C therapy effect body clear virus . Once enrol , participant randomly assign ( like flip coin ) receive telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 ( treatment group ) telaprevir + peginterferon alfa-2a + ribavirin ( control group ) . A total 80 participant , races/ethnicities , include study , 5 10 VA hospital study site ( 10 - 20 participants/site ) . Participants assign treatment group begin lead-in phase receive 5,000 IU vitamin D3 per day . Every two week lead-in phase , participant test determine Vitamin D level blood , well test , include HCV RNA ( determine amount virus present ) calcium level . Once adequate level Vitamin D detect participant ' blood , participant begin treatment telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 ( 15,000 IU/week ) 12 week . Participants randomize control group immediately begin treatment telaprevir + peginterferon alfa-2a + ribavirin 12 week . At end Week 12 participant ' involvement study complete . Adverse event effect vitamin D3 obtain assess participant ' medical history , physical examination , blood test clinic visit . HCV RNA assess Screening , Day 1 , Week 2 , 4 , 8 12 .</brief_summary>
	<brief_title>Vitamin D + Telaprevir + Peginterferon + Ribavirin Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Chronic Hepatitis C genotype 1 infection Treatment naïve Age &gt; 18 year Agree genetic test Liver disease hepatitis C HCV infection mixed genotype Decompensated liver disease AFP &gt; 100ng/ml . Known HIV infection Serum 25 ( OH ) D le 12ng/ml great 30ng/ml Regular vitamin D supplement use Regular calcium supplement use Refusal abstain vitamin D supplementation Current past history kidney stone Current use prohibit medication list section 5.5 INCIVEK® package insert . Need therapeutic vitamin D calcium ( e.g . treatment osteoporosis , osteomalacia , hyperparathyroidism etc . ) , opinion investigator Significant substance abuse within past 6 month , Suicidal attempt past 10 year suicidal ideation past 3 month , psychiatric condition investigator deems would make subject unsuited treatment peginterferon ribavirin . Confirmed suspect malignancy , history malignancy within past 3 year ( except treat basal cell carcinoma skin situ carcinoma uterine cervix ) Any autoimmune disease easily control ( opinion investigator ) Any condition result malabsorption ( Poorly control thyroid disorder , diabetes mellitus ( HbA1c &gt; 9 ) Glomerular disease ( e.g. , glomerulosclerosis glomerulonephritis ) associate serum creatinine &gt; 1.5 time upper limit normal Current history clinically significant cardiac abnormalities/dysfunction ( eg , angina , congestive heart failure , myocardial infarction , pulmonary hypertension , complex congenital heart disease , cardiomyopathy , significant arrhythmia ) include current uncontrolled hypertension history use antianginal agent cardiac condition ( Inclusion consider clearance cardiologist obtain . ) Receipt investigational drug within past 30 day Females positive pregnancy test time screening , breastfeed anticipate pregnancy within next 18 month , men pregnant partner Lack agreement subject use two form acceptable contraception History evidence significant illness , opinion investigator , would make patient , unsuitable study Laboratory Exclusions Hemoglobin : &lt; 12gm/dl male female Neutrophil : &lt; 1,200/mm3 Platelets : &lt; 90,000/mm3 INR : &gt; 1.5 Albumin : &lt; 3.2gm/dl Total Bilirubin : &gt; 2.0mg/dl HbA1c : &gt; 9.5 % Serum Creatinine : &gt; 1.5 time upper limit normal Serum Calcium Within local laboratory normal range Parathyroid hormone ( PTH ) &lt; 10 &gt; 55 pg/mL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>treatment-naive</keyword>
</DOC>